Anbio Biotechnology (NNNN): R&D Expense

Annual figures by period end, from SEC filings.

$201.3K

Year ended 2025-12-31

+0.2%

3-year compound annual growth

2022-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$201.3K	-55.7%	2026-04-07, From 2025-01-01
2024-12-31	$454.2K	+237.2%	2026-04-07, From 2024-01-01
2023-12-31	$134.7K	-32.7%	2026-04-07, From 2023-01-01
2022-12-31	$200.0K	n/a	2025-04-28, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Anbio Biotechnology (NNNN)	2025-12-31	$201.3K	-55.7%
Aspira Women's Health Inc. (AWHL)	2025-12-31	$2.88M	-11.9%
Biomerica Inc (BMRA)	2026-05-31	$788.0K	-23.0%
Insight Molecular Diagnostics Inc. (IMDX)	2025-12-31	$15.90M	+61.6%
Immucell Corp (ICCC)	2025-12-31	$3.04M	-22.0%
Alpha Teknova, Inc. (TKNO)	2025-12-31	$2.20M	-20.4%
Volitionrx Ltd (VNRX)	2025-12-31	$10.08M	-30.0%
Celldex Therapeutics, Inc. (CLDX)	2025-12-31	$245.07M	+49.8%
Intellia Therapeutics, Inc. (NTLA)	2025-12-31	$388.86M	-16.6%

Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗